Impact of tacrolimus-sirolimus maintenance immunosuppression on proteinuria and kidney function in pancreas transplant alone recipients

Transplantation

Volumn 94, Issue 9, 2012, Pages 940-946

  Kandula, Praveen ^a   Fridell, Jonathan ^a   Taber, Tim E ^a   Sharfuddin, Asif ^a   Yaqub, Muhammad S ^a   Phillips, Carrie L ^a   Chen, Jeannie ^a   Mujtaba, Muhammad ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Pancreas transplantation; Proteinuria; Sirolimus; Tacrolimus

Indexed keywords

CREATININE; INSULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL ANTIDIABETIC AGENT; PROTEIN; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ACNE; ACUTE KIDNEY FAILURE; ADULT; AGE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DEMOGRAPHY; DIABETES MELLITUS; DIARRHEA; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESOPHAGITIS; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HEMODIALYSIS; HUMAN; HYPERLIPIDEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; NEUTROPENIA; PANCREAS TRANSPLANTATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEINURIA; SEX DIFFERENCE; SIDE EFFECT;

ADULT; AGE FACTORS; BIOPSY; CREATININE; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PANCREAS TRANSPLANTATION; PROTEINURIA; RETROSPECTIVE STUDIES; SEX FACTORS; SIROLIMUS; TACROLIMUS;

EID: 84869494983     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182696a13     Document Type: Article

References (42)

1. Kaufman DB, Shapiro R, Lucey MR, et al. Immunosuppression: practice and trends. Am J Transplant 2004; 4(suppl 9): 38.
2. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
3. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
4. Flechner SM, Glyda M, Cockfield S, et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011; 11: 1633.
5. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036.
6. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252.
7. Mota A, Arias M, Taskinen EI, et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004; 4: 953.
8. Oberbauer R, Segoloni G, Campistol JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005; 18: 22.
9. Letavernier E, Pe'raldi MN, Pariente A, et al. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005; 80: 1198.
10. Morelon E, Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 2003; 35(3 suppl): 52S.
11. Ruiz JC, Campistol JM, Sanchez-Fructuoso A, et al. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimusbased treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant 2006; 21: 3252.
12. Hemmelgarn BR, Manns BJ, Lloyd A, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010; 303: 423.
13. Radermacher J, Mengel M, Ellis S, et al. The renal arterial resistance index and renal allograft survival. N Engl J Med 2003; 349: 115.
14. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: evolution in practice and trends, 1994Y2004. Am J Transplant 2006; 6(5 pt 2): 1111.
15. Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of June 2004. Clin Transplant 2005; 19: 433.
16. Gruessner AC, Sutherland DE, Gruessner RW. Pancreas transplantation in the United States: a review. Curr Opin Organ Transplant 2010; 15: 93.
17. Cantarovich D, Vistoli F. Minimization protocols in pancreas transplantation. Transpl Int 2009; 22: 61.
18. Drognitz O, Benz S, Pfeffer F, et al. Long-term follow-up of 78 simultaneous pancreas-kidney transplants at a single-center institution in Europe. Transplantation 2004; 78: 1802.
19. Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339: 69.
20. Gruessner RW, Sutherland DE, Kandaswamy R, et al. Over 500 solitary pancreas transplants in nonuremic patients with brittle diabetes mellitus. Transplantation 2008; 85: 42.
21. Fioretto P, Sutherland DE, Najafian B, et al. Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients. Kidney Int 2006; 69: 907.
22. Chatzizacharias NA, Vaidya A, Sinha S, et al. Risk analysis for deterioration of renal function after pancreas alone transplant. Clin Transplant 2011; 26: 387.
23. Smail N, Paraskevas S, Tan X, et al. Renal function in recipients of pancreas transplant alone. Curr Opin Organ Transplant 2012; 17: 73.
24. Fioretto P, Najafian B, Sutherland DE, et al. Tacrolimus and cyclosporine nephrotoxicity in native kidneys of pancreas transplant recipients. Clin J Am Soc Nephrol 2011; 6: 101.
25. Chhabra D, Skaro AI, Leventhal JR, et al. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Clin J Am Soc Nephrol 2012; 7: 504.
26. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant 2005; 5: 2273.
27. Mendez R, Gonwa T, Yang HC, et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation 2005; 80: 303.
28. McTaggart RA, Gottlieb D, Brooks J, et al. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 2003; 3: 416.
29. Napoli KL, Taylor PJ. From beach to bedside: history of the development of sirolimus. Ther Drug Monit 2001; 23: 559.
30. Anil Kumar MS, Heifets M, Fyfe B, et al. Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy. Transplantation 2005; 80: 807.
31. Tedesco Silva H Jr, Cibrik D, Johnston T, et al. Everolimus plus reducedexposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010; 10: 1401.
32. Coppelli A, Giannarelli R, Boggi U, et al. Disappearance of nephrotic syndrome in type 1 diabetic patients following pancreas transplant alone. Transplantation 2006; 81: 1067.
33. Coppelli A, Giannarelli R, Vistoli F, et al. The beneficial effects of pancreas transplant alone on diabetic nephropathy. Diabetes Care 2005; 28: 1366.
34. Guba M, Pratschke J, Hugo C, et al. Early conversion to a sirolimusbased, calcineurin-inhibitorYfree immunosuppression in the SMART trial: observational results at 24 and 36 months after transplantation. Transpl Int 2012; 25: 416.
35. Abdelmalek MF, Humar A, Stickel F, et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant 2012; 12: 694.
36. Biancone L, Bussolati B, Mazzucco G, et al. Loss of nephrin expression in glomeruli of kidney-transplanted patients under m-TOR inhibitor therapy. Am J Transplant 2010; 10: 2270.
37. Letavernier E, Bruneval P, Vandermeersch S, et al. Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant 2009; 24: 630.
38. Letavernier E, Bruneval P, Mandet C, et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007; 2: 326.
39. Myers BD, Sibley R, Newton L, et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 1988; 33: 590.
40. Takeda A, Uchida K, Haba T, et al. Chronic cyclosporin nephropathy: long-term effects of cyclosporin on renal allografts. Clin Transplant 2001; 15(suppl 5): 22.
41. Senior PA, Paty BW, Cockfield SM, et al. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant 2005; 5: 2318.
42. McKenna GJ, Trotter JF. Sirolimus conversion for renal dysfunction in liver transplant recipients: the devil really is in the details. Am J Transplant 2012; 12: 521.